83_FR_10546 83 FR 10499 - National Institute on Drug Abuse; Notice of Closed Meetings

83 FR 10499 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 47 (March 9, 2018)

Page Range10499-10499
FR Document2018-04804

Federal Register, Volume 83 Issue 47 (Friday, March 9, 2018) 
[Federal Register Volume 83, Number 47 (Friday, March 9, 2018)]
[Notices]
[Page 10499]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-04804]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel Cutting-Edge Basic Research Awards (CEBRA) (R21).
    Date: March 20, 2018.
    Time: 12:00 p.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive 
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel Development of a Device to Objectively Measure Pain 
(R41/R42/R43/R44).
    Date: March 29, 2018.
    Time: 9:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852.
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel HIV-associated Neuropathic Pain and Opioid 
Interaction (R01).
    Date: March 29, 2018.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: March 6, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-04804 Filed 3-8-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 47 / Friday, March 9, 2018 / Notices 10499 (Catalogue of Federal Domestic Assistance Name of Committee: National Institute on of Biomedical Imaging and Bioengineering Program No. 93.242, Mental Health Research Drug Abuse Special Emphasis Panel HIV- National Institutes of Health, 6707 Grants, National Institutes of Health, HHS) associated Neuropathic Pain and Opioid Democracy Blvd., Bethesda, MD 20892, (301) Interaction (R01). 451–4794, dennis.hlasta@nih.gov. Dated: March 6, 2018. Date: March 29, 2018. Dated: March 6, 2018. Melanie J. Pantoja, Time: 11:00 a.m. to 3:00 p.m. Program Analyst, Office of Federal Advisory Agenda: To review and evaluate grant David Clary, Committee Policy. applications. Program Analyst, Office of Federal Advisory [FR Doc. 2018–04805 Filed 3–8–18; 8:45 am] Place: National Institutes of Health, Committee Policy. BILLING CODE 4140–01–P Neuroscience Center, 6001 Executive [FR Doc. 2018–04803 Filed 3–8–18; 8:45 am] Boulevard, Rockville, MD 20852 (Telephone BILLING CODE 4140–01–P Conference Call). DEPARTMENT OF HEALTH AND Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of DEPARTMENT OF HEALTH AND HUMAN SERVICES Extramural Policy and Review, Division of HUMAN SERVICES Extramural Research, National Institute on National Institutes of Health Drug Abuse, NIH, DHHS, 6001 Executive National Institutes of Health Boulevard, Room 4234, MSC 9550, Bethesda, National Institute on Drug Abuse; MD 20892, 301–827–5840, Government-Owned Inventions; Notice of Closed Meetings julia.berzhanskaya@nih.gov. Availability for Licensing Pursuant to section 10(d) of the (Catalogue of Federal Domestic Assistance Federal Advisory Committee Act, as Program Nos.: 93.279, Drug Abuse and AGENCY: National Institutes of Health, amended, notice is hereby given of the Addiction Research Programs, National HHS. following meetings. Institutes of Health, HHS) ACTION: Notice. The meetings will be closed to the Dated: March 6, 2018. public in accordance with the Natasha M. Copeland, SUMMARY: The invention listed below is provisions set forth in sections owned by an agency of the U.S. Program Analyst, Office of Federal Advisory 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Committee Policy. Government and is available for as amended. The grant applications and licensing to achieve expeditious [FR Doc. 2018–04804 Filed 3–8–18; 8:45 am] the discussions could disclose commercialization of results of BILLING CODE 4140–01–P confidential trade secrets or commercial federally-funded research and property such as patentable material, development. Foreign patent and personal information concerning applications are filed on selected DEPARTMENT OF HEALTH AND individuals associated with the grant inventions to extend market coverage HUMAN SERVICES applications, the disclosure of which for companies and may also be available would constitute a clearly unwarranted National Institutes of Health for licensing. invasion of personal privacy. FOR FURTHER INFORMATION CONTACT: National Institute of Biomedical Jenish Patel, Ph.D., 240–669–2894; Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Cutting- Imaging and Bioengineering; Notice of jenish.patel@nih.gov. Licensing Edge Basic Research Awards (CEBRA) (R21). Closed Meeting information and copies of the U.S. Date: March 20, 2018. patent application listed below may be Pursuant to section 10(d) of the Time: 12:00 p.m. to 8:00 p.m. obtained by communicating with the Agenda: To review and evaluate grant Federal Advisory Committee Act, as indicated licensing contact at the applications. amended, notice is hereby given of the Technology Transfer and Intellectual Place: National Institutes of Health, following meeting. The meeting will be closed to the Property Office, National Institute of Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual public in accordance with the Allergy and Infectious Diseases, 5601 Meeting). provisions set forth in sections Fishers Lane, Rockville, MD 20852; tel. Contact Person: Susan O. McGuire, Ph.D., 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 301–496–2644. A signed Confidential Scientific Review Officer, Office of as amended. The grant applications and Disclosure Agreement will be required Extramural Policy and Review, National to receive copies of unpublished patent Institute on Drug Abuse, National Institutes the discussions could disclose confidential trade secrets or commercial applications. of Health, DHHS, 6001 Executive Blvd., property such as patentable material, SUPPLEMENTARY INFORMATION: Room 4245, Rockville, MD 20852, (301) 827– 5817, mcguireso@mail.nih.gov. and personal information concerning Technology description follows. Name of Committee: National Institute on individuals associated with the grant Protein Nanoparticles for Antigen Drug Abuse Special Emphasis Panel applications, the disclosure of which Display in Vaccines Development of a Device to Objectively would constitute a clearly unwarranted Measure Pain (R41/R42/R43/R44). invasion of personal privacy. Description of Technology Date: March 29, 2018. The technology relates to a protein- Time: 9:00 a.m. to 3:00 p.m. Name of Committee: National Institute of Agenda: To review and evaluate grant Biomedical Imaging and Bioengineering based nanoparticle platform that allows applications. Special Emphasis Panel; BRAIN Initiative: presentation of immunogenic molecules Place: National Institutes of Health, Theories, Models and Methods for Analysis such as influenza virus antigens. This Neuroscience Center, 6001 Executive of Complex Data for the Brain, (2018/08). protein platform is made up of hepatitis Boulevard, Rockville, MD 20852. Date: April 12, 2018. B capsid/core proteins. The core Time: 8:00 a.m. to 7:00 p.m. amozie on DSK30RV082PROD with NOTICES Contact Person: Julia Berzhanskaya, Ph.D., proteins contain immunogenic loop c/ Scientific Review Officer, Office of Agenda: To review and evaluate grant e1, where other antigens can be inserted Extramural Policy and Review, Division of applications. Extramural Research, National Institute on Place: Residence Inn Arlington Capital and the chimeric protein retains the Drug Abuse, NIH, DHHS, 6001 Executive View, 2850 South Potomac Avenue, ability to form capsid-like particles. The Boulevard, Room 4234, MSC 9550, Bethesda, Arlington, VA 22202. technology describes the insertion of MD 20892, 301–827–5840, Contact Person: Dennis Hlasta, Ph.D., one or more copies of influenza epitopes julia.berzhanskaya@nih.gov. Scientific Review Officer, National Institute derived from the globular head or the VerDate Sep<11>2014 16:47 Mar 08, 2018 Jkt 244001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\09MRN1.SGM 09MRN1


Document Created: 2018-03-09 03:48:52
Document Modified: 2018-03-09 03:48:52
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMarch 20, 2018.
FR Citation83 FR 10499 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR